Industry
Biotechnology
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Loading...
Open
2.61
Mkt cap
731M
Volume
367K
High
2.65
P/E Ratio
-3.27
52-wk high
3.45
Low
2.53
Div yield
N/A
52-wk low
1.64
Portfolio Pulse from
November 12, 2024 | 9:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 4:14 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 10:28 am
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
September 25, 2024 | 5:36 pm
Portfolio Pulse from Benzinga Newsdesk
September 25, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 3:52 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 6:13 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 8:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.